Lyell Immunopharma, Inc. (LYEL) Earnings Call Transcripts

Lyell Immunopharma, Inc.'s Latest Earnings Call - May 20, 2026

In the Q1 2026 earnings call for Lyell Immunopharma, the company highlighted significant advancements in its lead CAR-T therapy, ronde-cel, particularly in treating large B-cell lymphoma. The therapy demonstrated a 93% overall response rate and an 18-month median progression-free survival, which are notably superior to existing CD19 CAR therapies. Management maintained guidance for pivotal data disclosure in mid-2027 and indicated strong cash reserves of $261 million, sufficient to support operations through Q3 2027. These developments could positively influence stock performance as they signal robust clinical efficacy and a solid financial position.

Reported metrics

Guidance from management

Lyell maintained its guidance for pivotal data disclosure in mid-2027 and indicated that they are on track to submit a BLA by the end of 2027.

What management said

So the great news for us is we have, as we've just spoken about some data-rich catalysts coming up here in the next period of time. We have -- as of our Q1 filing, we had $261 million in cash, and that gets us through Q3 of next year and through these catalysts, including the pivotal data.

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape, particularly with the recent withdrawal of J&J from the CD19/CD20 CAR-T market and the potential impact of emerging therapies. There were also questions about the regulatory environment and the implications for approval timelines.

Main topics on the call

• Clinical Efficacy of ronde-cel — Lyell's ronde-cel therapy achieved a 93% overall response rate and a 76% complete response rate in third-line large B-cell lymphoma patients, with a median progression-free survival of 18 months. Lynn Seely stated, 'It's...
• Regulatory Environment and Strategy — Management expressed optimism about receiving FDA approval based on the ongoing single-arm study, stating, 'Our FDA interactions to date have suggested that a full approval could be possible.' They also mentioned the imp...
• Manufacturing Capabilities — Lyell's state-of-the-art manufacturing facility can produce over 1,200 doses of ronde-cel annually, which supports their launch plans. Seely noted, 'We can manufacture more than 1,200 doses per year, which can get us wel...
• Financial Position — Lyell reported a cash balance of $261 million, which is expected to sustain operations through Q3 2027. This financial stability positions the company well for upcoming clinical data releases.

Read the full Lyell Immunopharma, Inc. transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 Lyell Immunopharma, Inc. earnings call transcripts on record, spanning January 15, 2025 to June 8, 2026. Based on this history, Lyell Immunopharma, Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LYEL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

8

First call

January 15, 2025

Most recent

June 8, 2026

Reporting cadence

quarterly